-
1Academic Journal
Authors: Margarita P. Zaikina, Maksim I. Tkachev, Veronika V. Kogaj, Elizaveta S. Tabachenkova, Anna A. Kudryavceva, Dmitrij A. Napalkov, Marina I. Sekacheva, Anastasiya A. Sokolova, Маргарита Павловна Заикина, Максим Игоревич Ткачёв, Вероника Валерьяновна Когай, Елизавета Сергеевна Табаченкова, Анна Александровна Кудрявцева, Дмитрий Александрович Напалков, Марина Игоревна Секачева, Анастасия Андреевна Соколова
Contributors: Авторы заявляют об отсутствии финансирования исследования.
Source: Complex Issues of Cardiovascular Diseases; Том 14, № 1 (2025); 169-179 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 1 (2025); 169-179 ; 2587-9537 ; 2306-1278
Subject Terms: Сердечно-сосудистое заболевание, Venous thrombosis, Arterial thrombosis, Cancer, Cardiovascular disease, Венозный тромбоз, Артериальный тромбоз, Онкологическое заболевание
File Description: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/1570/1008; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1851; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1852; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1570/1853; ReFaey K, Tripathi S, Grewal SS, et al. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):645-653. doi:10.1016/j.mayocpiqo.2021.05.005; Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457-1467. doi:10.1056/NEJMra1100265; de Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361-371. doi:10.1007/s10585-021-10106-x; De Boer RA, Meijers WC, Van Der Meer P, Van Veldhuisen DJ. Cancer and heart disease: associations and relations. European J of Heart Fail. 2019;21(12):1515-1525. doi:10.1002/ejhf.1539; Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. doi:10.1016/j.ihj.2023.09.004; Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x; Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181-1201. doi:10.6004/jnccn.2021.0047; Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017; Pateras I, Giaginis C, Tsigris C, Patsouris E, Theocharis S. NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opinion on Therapeutic Targets. 2014;18(9):1089-1101. doi:10.1517/14728222.2014.938051; Buziashvili JI, Stilidi IS, Mackeplishvili ST, et al. Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects. Annals RAMS. 2023;78(2):132-140. doi:10.15690/vramn8359; Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1; Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343-351. doi:10.1016/j.atherosclerosis.2017.06.001; Genovesi S, Giussani M, Orlando A, Lieti G, Viazzi F, Parati G. Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents. Pediatr Nephrol. 2022;37(3):537-545. doi:10.1007/s00467-021-05144-2; Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-1231. doi:10.1634/theoncologist.2016-0414; Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. doi:10.1002/cncr.23062; Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. doi:10.1038/s41572-022-00336-y; Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study. Thromb Haemost. 2017;117(01):57-65. doi:10.1160/TH15-08-0686; Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagulation & Fibrinolysis. 2008;19(2):159-165. doi:10.1097/MBC.0b013e3282f54558; Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: What Have We Learned and What Questions Remain? Drugs & Aging. 1999;15(6):419-422. doi:10.2165/00002512-199915060-00001; Jezovnik MK, Poredos P, Lusa L. Idiopathic Venous Thrombosis is Associated with Preclinical Atherosclerosis. JAT. 2010;17(3):304-311. doi:10.5551/jat.3079; Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z. Diabetes is associated with increased risk of venous thromboembolism: A systematic review and meta-analysis. Thrombosis Research. 2015;135(1):90-95. doi:10.1016/j.thromres.2014.11.003; Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024;46(2):2431149. doi:10.1080/0886022X.2024.2431149; Lees JS, Ho F, Parra-Soto S, et al. Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. eClinicalMedicine. 2021;38:101030. doi:10.1016/j.eclinm.2021.101030; Roach REJ, Lijfering WM, Tait RC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis. 2015;13(10):1815-1822. doi:10.1111/jth.13116; Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24(4):3169. doi:10.3390/ijms24043169
-
2Dissertation/ Thesis
Contributors: Мельникова, М. Л.
Subject Terms: ВРЕМЕННАЯ ПЕРСПЕКТИВА, КОНЦЕПТУАЛЬНАЯ МОДЕЛЬ ФОРМИРОВАНИЯ СМЫСЛОВОГО БУДУЩЕГО, СМЫСЛОВОЕ БУДУЩЕЕ, ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, СМЫСЛОЖИЗНЕННЫЕ ОРИЕНТАЦИИ, ЖИЗНЕННЫЙ СМЫСЛ
Access URL: https://elar.uspu.ru/handle/ru-uspu/65051
-
3Academic Journal
Authors: S. M. Kharit, I. V. Fridman, A. A. Ruleva, С. М. Харит, И. В. Фридман, А. А. Рулева
Source: Epidemiology and Vaccinal Prevention; Том 23, № 2 (2024); 71-77 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 2 (2024); 71-77 ; 2619-0494 ; 2073-3046
Subject Terms: онкологическое заболевание, measles, immunodeficiency, oncological disease, корь, иммунодефицит
File Description: application/pdf
Relation: https://www.epidemvac.ru/jour/article/view/1972/1024; Pergam S., Englund J., Kamboj M., et al. Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy./ Biol Blood Marrow Transplant. 2019 Vol.25, N11. P. 321–330.; Gray M., Hann I., Jones S., Atevens R., et al. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review./ British medical journal. 1987 Vol. 295. P. 19–22.; Marron M., Brackmann L.K., Kuhse P., et al. Vaccination and the Risk of Childhood Cancer. A Systematic Review and Meta-Analysis./ Front Oncol. 2021 Vol. 10. P. 610843.; Vandeborne L., Pantziarka P., Nuffel V., et al. Repurposing Infectious Diseases Vaccines Against Cancer./ Front Oncol. 2021 Vol. 11, N1. P. 688–755.; Stephen J, Babovic-Vuksanovic D., Bexon A. , et al. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination./ Mayo Clin Proc. 2019 Vol. 94, N9. P. 1834–1839.; Marquis S., Logue J., Chu H., et al. Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer./ JAMA Network Open. 2021 Vol. 4, N4. P. e2118508.; Abdelaziz T. A., Atfy M., Risha A.I., et al. Assessment of Humoral Immunity to Measles Virus in Cancer Survivor Children after Chemotherapy: A Case-Control Study. Fetal and Pediatric Pathology. 2021 Vol. 41, N5. P. 711–721.; Харит С. М., Черняева Т. В., Черняева Е. В. и др. Вакцинация пациентов с онкологическими заболеваниями против кори и эпидемического паротита. Инфекция и иммунитет. 2011 Т.1, №1. С. 85–91.; Pergam S. A., Englund J. A., Kamboj M., et al. Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy./ Biol. Blood Marrow Transplant. 2019 Vol. 25. P. e321 e330.; Fouda A. E., Kandil S., Boujettif F., et al. Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination./ Hematology. 2018 Vol. 23, N9. P. 590–595.; Брусов Н. К. Тактика вакцинации против кори детей, прошедших курс терапии злокачественных заболеваний: Дис. канд. мед. наук. 2005, 113 с., Санкт-Петербург; 2005. Доступно на: https://www.dissercat.com/content/taktika-vaktsinatsii-protiv-kori-detei-proshedshikh-terapiyu-zlokachestvennykh-zabolevanii Ссылка активна на 10.01.2023; https://www.epidemvac.ru/jour/article/view/1972
-
4Report
-
5Academic Journal
Authors: Станислав Николаевич Антонцев, Александр Алексеевич Папин, Маргарита Андреевна Токарева, Эвелина Ивановна Леонова, Екатерина Александровна Гридюшко
Source: Известия Алтайского государственного университета, Iss 4(120), Pp 71-80 (2021)
Subject Terms: математическое моделирование, моделирование опухолей, онкологическое заболевание, многомасштабные модели, многофазные системы, Physics, QC1-999, History (General), D1-2009
File Description: electronic resource
-
6Academic Journal
Authors: Bagrat G. Alekyan, Narek G. Karapetyan, Aleksandr A. Gritskevich, Lilit G. Gyoletsyan, Arthur V. Galstyan, Amiran Sh. Revishvili, Баграт Гегамович Алекян, Нарек Григорьевич Карапетян, Александр Анатольевич Грицкевич, Лилит Генриковна Гёлецян, Артур Варужанович Галстян, Амиран Шотаевич Ревишвили
Contributors: Авторы заявляют об отсутствии финансирования исследования.
Source: Complex Issues of Cardiovascular Diseases; Том 12, № 3 (2023); 98-108 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 12, № 3 (2023); 98-108 ; 2587-9537 ; 2306-1278
Subject Terms: Чрескожное коронарное вмешательство, Cancer, Malignant neoplasms, Percutaneous coronary intervention, Онкологическое заболевание, Злокачественные новообразования
File Description: application/pdf
Relation: https://www.nii-kpssz.com/jour/article/view/1230/815; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1230/1247; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1230/1248; Pearse R.M., Clavien P.A., Demartines N., Fleisher L.A., Grocott M., Haddow J., et al.; International Surgical Outcomes Study group. Global patient outcomes after elective surgery: Prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth. 2016;117(5):601-609. doi:10.1093/bja/aew316. Erratum in: Br J Anaesth. 2017;119(3):553.; World health statistics 2021: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2021. Available at: https://apps.who.int/iris/handle/10665/342703. (accessed 23.06.2023); Al-Kindi S.G., Oliveira G.H. Prevalence of Preexisting Cardiovascular Disease in Patients with Different Types of Cancer the Unmet Need for Onco-Cardiology. Mayo Clinic Proceedings. 2016; 91:81–3. doi:10.1016/j.mayocp.2015.09.009.; Koene R.J., Prizment A.E., Blaes A., Konety S.H. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133:1104–14. doi:10.1161/CIRCULATIONAHA.115.020406.; Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70(8):926-938. doi:10.1016/j.jacc.2017.06.047.; Zamorano J.L., Lancellotti P., Muñoz D.R., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M.; ESC Scientific Document Group 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC). Russian Journal of Cardiology 2017;143. doi:10.15829/1560-4071-2017-3-105-139.; Das D., Asher A., Ghosh A.K. Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges. Curr Treat Options Oncol. 2019;20(6):46. doi:10.1007/s11864-019-0644-3.; Lyon A.Rr, López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal. 2022;43:4229–361. doi:10.1093/eurheartj/ehac244.; da Silva R.M.F.L. Effects of Radiotherapy in Coronary Artery Disease. Curr Atheroscler Rep. 2019;21(12):50. doi:10.1007/s11883-019-0810-x.; Sardar P., Kundu A., Chatterjee S., Nohria A., Nairooz R., Bangalore S., Mukherjee D., Aronow W.S., Lavie C.J. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis Clin Cardiol. 2017;40(2):73-81. doi:10.1002/clc.22631.; Трашков А.П., Васильев А.Г., Цыган Н.В., Хайцев Н.В., Марченко С.П., Наумов А.Б., Колесниченко А.В., Хубулава Г.Г., Суворов В.В., Кравцова А.А. Антитромботическая терапия в онкологии: современное состояние проблемы и нерешенные вопросы. Педиатр. 2012;3(2):3-19.; Johnstone C., Rich S.E. Bleeding in cancer patients and its treatment: a review. Annals of Palliative Medicine 2018;7:265–73. doi:10.21037/apm.2017.11.01.; Devereaux P.J., Goldman L., Cook D.J., Gilbert K., Leslie K., Guyatt G.H. Perioperative cardiac events in patients undergoing noncardiac surgery: A review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ. 2005;173(6):627-34. doi:10.1503/cmaj.050011.; Botto F., Alonso-Coello P., Chan M.T.V., Villar J.C., Xavier D., Srinathan S.K., et al. Myocardial Injury after Noncardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes. Anesthesiology. 2014;120(3):564-78. doi:10.1097/ALN.0000000000000113.; Devereaux P.J., Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. European Heart Journal 2020;41:3083–91. doi:10.1093/eurheartj/ehz301.; Writing Committee for the VISION Study Investigators; Devereaux P.J., Biccard B.M., Sigamani A., Xavier D., Chan M.T.V., Srinathan S.K, et al. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA. 2017;317:1642. doi:10.1001/jama.2017.4360.; Mol K.H.J.M., Hoeks S.E, Liem V.G.B., Stolker R.J, van Lier F. Postoperative troponin release is associated with major adverse cardiovascular events in the first year after noncardiac surgery. Int J Cardiol. 2019;280:8-13. doi:10.1016/j.ijcard.2019.01.035.; Halvorsen S., Mehilli J., Cassese S., Hall T.S., Abdelhamid M., Barbato E., et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270.; Dalton M.L., Parker T.M., Mistrot J.J., Bricker D.L. Concomitant coronary artery bypass and major noncardiac surgery. J Thorac Cardiovasc Surg. 1978;75(4):621-4. doi:10.1016/s0022-5223(19)41251-8.; Miller D.L., Orszulak T.A., Pairolero P.C., Trastek V.F., Schaff H.V. Combined operation for lung cancer and cardiac disease. Ann Thorac Surg. 1994;58(4):989-93; discussion 993-4. doi:10.1016/0003-4975(94)90442-1.; Danton M.H.D, Anikin V.A., McManus K.G., McGuigan J.A., Campalani G. Simultaneous cardiac surgery with pulmonary resection: Presentation of series and review of literature. Eur J Cardiothorac Surg. 1998;13(6):667-72. doi:10.1016/s1010-7940(98)00088-8.; Ma X. Huang F., Zhang Z., Song F., Ou S. Lung cancer resection with concurrent off-pump coronary artery bypasses: safety and efficiency J Thorac Dis. 2016;8(8):2038-45. doi:10.21037/jtd.2016.07.67.; Guha A., Dey A.K., Kalra A., Gumina R., Lustberg M., Lavie C.J., Sabik J.F. 3rd, Addison D. Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States. Mayo Clinic Proceedings. 2020;95:1865–76. doi:10.1016/j.mayocp.2020.05.044.; Давыдов М.И., Акчурин Р.С., Герасимов С.С., Дземешкевич С.Л., Бранд Я.Б., Долгов И.М. Сочетанное хирургическое лечение онкологических больных с конкурирующими сердечно-сосудистыми заболеваниями при опухолевых поражениях легких и средостения. Хирургия Журнал им. Н.И. Пирогова. 2010:4–10.; Порханов В.А., Барбухатти К.О., Кононенко В.Б., Белаш С.Ю., Коваленко А.Л., Скопец А.А., Ситник С.Д., Поляков И.С. Одномоментные операции на сердце и легком при ИБС и злокачественной патологии легкого в условиях искусственного кровообращения. Клиническая и экспериментальная Хирургия 2013; (1). 17–23.; Порханов В.А., Барбухатти К.О., Кононенко В.Б., Белаш С.А., Коваленко А.Л., Скопец А.А., Ситник С.Д., Поляков И.С. Симультанные операции при сочетании рака легкого и ишемической болезни сердца. Грудная и сердечно-сосудистая Хирургия. 2016; 58(2):114–21; Герасимов С.С., Давыдов М.И., Давыдов М.М. Современная стратегия хирургического лечения онкологических больных с тяжёлыми сопутствующими сердечно-сосудистыми заболеваниями. Российский онкологический журнал 2018;23:3–6. doi:10.18821/1028-9984-2018-23-3-6-120-128.; Алекян Б.Г., Григорьян А.М., Стаферов А.В., Карапетян Н.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации - 2021 год. Эндоваскулярная хирургия. 2022;9 (Спец.выпуск): S5-S254. doi:10.24183/2409-4080-2022-9S-S5-S254.; Ciriaco P., Carretta A., Calori G., Mazzone P., Zannini P. Lung resection for cancer in patients with coronary arterial disease: Analysis of short-term results. Eur J Cardiothorac Surg. 2002;22(1):35-40. doi:10.1016/s1010-7940(02)00209-9.; Voltolini L., Rapicetta C., Luzzi L., Paladini P., Ghiribelli C., Scolletta S., Fineschi M., Gotti G. Lung resection for non-small cell lung cancer after prophylactic coronary angioplasty and stenting: Short- and long-term results. Minerva Chirurgica. 2012;67(1):77-85.; Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P., De Belder M.A., Kwok C.S., Rashid M., Fischman D.L., Mamas M.A. Percutaneous coronary intervention in cancer patients: A report of the prevalence and outcomes in the United States. European Heart Journal. 2019;40(22):1790-1800. doi:10.1093/eurheartj/ehy769.; Никитина Т. Г., Домбровский М. М., Алекян Б. Г., Давыдов М. И., Бокерия Л. А. Стентирование коронарных артерий у больных с ишемической болезнью сердца и онкопатологией. Креативная кардиология. 2016;10:296–305. doi:10.15275/kreatkard.2016.04.04.; Андрущук В.В., Полонецкий О.Л., Островский Ю.П., Курганович С.А., Геворкян Т.Т., Курушко Т.В. Стентирование коронарных артерий у пациентов с опухолями основных локализаций и сопутствующей ишемической болезнью сердца. Кардиология в Беларуси. 2020;12:483–94. doi:10.34883/PI.2020.12.4.004.; Алекян Б.Г., Ручкин Д.В., Карапетян Н.Г., Иродова Н.Л., Мелешенко Н.Н., Гелецян Л.Г. Клинический случай гибридного лечения пациента с критическим стенозом аортального клапана, поражением ствола левой коронарной артерии и кровоточащим раком желудка. Патология кровообращения и кардиохирургия. 2022;26:58. doi:10.21688/1681-3472-2022-2-58-65.; Baquet M., Jochheim D., Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. Journal of Interventional Cardiology. 2018;31:330–7. doi:10.1111/joic.12499.; Urban P., Meredith I.T., Abizaid A., Pocock S.J., Carrié D., Naber C., ipiecki J., Richardt G., Iñiguez A., Brunel P., Valdes-Chavarri M., Garot P., Talwar S., Berland J., Abdellaoui M., Eberli F., Oldroyd K., Zambahari R., Gregson J., Greene S., Stoll H.P., Morice M.C.; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. New England Journal of Medicine. 2015; 373(21):2038-47. doi:10.1056/nejmoa1503943.
-
7Academic Journal
Authors: G. R. Ramazanov, E. A. Kovaleva, N. A. Shamalov, Г. Р. Рамазанов, Э. А. Ковалева, Н. А. Шамалов
Source: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 10, № 4 (2021); 778-786 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 10, № 4 (2021); 778-786 ; 2541-8017 ; 2223-9022
Subject Terms: патогенез, cryptogenic stroke, oncologic disease, pathogenesis of ischemic stroke, криптогенный инсульт, онкологическое заболевание
File Description: application/pdf
Relation: https://www.jnmp.ru/jour/article/view/1283/1005; https://www.jnmp.ru/jour/article/view/1283/1107; Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–438. PMID: 24646875 https://doi.org/10.1016/S1474-4422(13)70310-7; Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. PMID: 7678184 https://doi.org/10.1161/01.STR.24.1.35; Harloff A, Schlachetzki F. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018;379(10):986– 987. https://doi.org/10.1056/NEJMoa1802686; Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et.al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019;380(200):1906–1917. https://doi.org/10.1056/NEJMoa1813959; AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke (ARCADIA). 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03192215. [Accessed Jul 09,2021]; Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS). 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02427126 [Accessed Jul 09.2021]; Ntaios G, Perlepe K, Lambrou D, Sirimarco G, Strambo D, Eskandari A, et al. Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source. J Am Heart Assoc. 2019;8: e012858. PMID: 31364451 https://doi.org/10.1161/JAHA.119.012858; Kim SJ, Park JH, Lee MJ, Park YG, Ahn MJ, Bang OY. Clues to occult cancer in patients with ischemic stroke. PLoS One. 2012;(9)7:e44959. PMID: 22984594 https://doi.org/10.1371/journal.pone.0044959; Graus F, Rogers LR, Posner JM. Cerebrovascular complication in patients with cancer. Medicine (Baltimore). 1985;64(1):16–35. PMID: 3965856 https://doi.org/10.1097/00005792-198501000-00002; Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280–287. PMID: 27081658 https://doi.org/10.1002/acn3.291; Chen PC, Muo CH, Lee YT, Yu YH, Sung FC. Lung cancer and incidence of stroke: a population – based cohort study. Stroke. 2011;42(11):3034–3039. PMID: 21903961 https://doi.org/10.1161/STROKEAHA.111.615534; Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and Embolic Stroke of Undetermined Source. Stroke. 2021;52(3):1121–1130. PMID: 33504187 https://doi.org/10.1161/STROKEAHA.120.032002; Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019;381(14):1378–1386. PMID: 31577882 https://doi.org/10.1056/NEJMsr1905447; Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. PMID: 32786189 https://doi.org/10.1056/NEJMoa1916623; Navi BB, Howard G, Howard VJ, Zhao H, Judd SE, Elkind MSV, et al. New diagnosis of cancer and the risk of subsequent cerebrovascular events. Neurology. 2018;90(23):e2025–e2033. PMID: 29728524 https://doi.org/10.1212/WNL.0000000000005636; Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926–938. PMID: 28818202 https://doi.org/10.1016/j.jacc.2017.06.047; Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, et al. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. Stroke. 2014;45(8):2292–2297. PMID: 24994717 https://doi.org/10.1161/STROKEAHA.114.005784; Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–872. PMID: 28265016 https://doi.org/10.1161/STROKEAHA.116.016414; Navi BB, DeAngelis LM, Segal AZ. Multifocal strokes as the presentation of occult lung cancer. J Neurooncol. 2007;85(3):307–309. PMID: 17611718 https://doi.org/10.1007/s11060-007-9419-y; Navi BB, Kawaguchi K, Hriljac I, Lavi E, DeAngelis LM, Jamieson DG. Multifocal stroke from tumor emboli. Arch Neurol. 2009;66(9):1174– 1175. PMID: 19752313 https://doi.org/10.1001/archneurol.2009.172; Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand. 2009;119(1):1–16. PMID: 18616624 https://doi.org/10.1111/j.1600-0404.2008.01059.x; Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133(8):781–789. PMID: 30578253 https://doi.org/ 10.1182/blood-2018-06-860874; Selvik HA, Bjerkreim AT, Thomassen L, Waje-Andreassen U, Naess H, Kvistad CE. When to screen ischaemic stroke patients for cancer. Cerebrovasc Dis. 2018;45(1-2):42–47. PMID: 29402826 https://doi.org/10.1159/000484668; Gon Y, Sakaguchi M, Takasugi J, Kawano T, Kanki H, Watanabe A, et al. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke. Eur J Neurol. 2017;24(3):503–508. PMID: 28026909 https://doi.org/10.1111/ene.13234; Cocho D, Gendre J, Boltes A, Espinosa J, Ricciardi AC, Pons J, et al. Predictors of occult cancer in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2015;24(6):1324–1328. PMID: 25881772 https://doi.org/ 10.1016/j.jstrokecerebrovasdis.2015.02.006; Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, Ahn MJ, et al. CancerRelated Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. Stroke. 2020;22(1):1–10 PMID: 32027788 https://doi.org/10.5853/jos.2019.02278; Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry. 2006;77:1336–1339. PMID: 16847046 https://doi.org/10.1136/jnnp.2006.092940; Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–655. PMID: 22893596 https://doi.org/10.1002/cncr.27772; Thompson CM, Rodgers LR. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci. 1952;223:469–478. PMID: 14923654 https://doi.org/10.1097/00000441-195205000-00001; Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–220. PMID: 22758622. https://doi.org/10.2174/157340311799960645; Kim SG, Hong JM, Kim HY, Lee J, Chung PW, Park KY, et al. Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke. 2010;41:798–801. PMID: 20150545 https://doi.org/10.1161/STROKEAHA.109.571356; Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, et al. Stroke and cancer: the importance of cancer – associated hypercoagulation as a possible stroke etiology. Stroke. 2012;43:3029–3034. PMID: 22996958 https://doi.org/10.1161/STROKEAHA.112.658625; Sheng B, Fong MK, Chu YP, Cheong AP, Teng SK, Chu JP, et al. Stroke and cancer: misfortunes never come singularly. Int J Stroke. 2013;8:E30. PMID: 23879755 https://doi.org/10.1111/ijs.12071; Virchow R. Gesammalte Abhandlungen zur Wissenschaftlichen Medtzin. Frankfurt, Germany: Medinger Sohn; 1856.; Von Tempelhoff GF, Heilmann L, Hommel G, Pollow K. Impact of rheological variables in cancer. Semin Thromb Hemost. 2003;29(5):499– 513. PMID: 14631550 https://doi.org/10.1055/s-2003-44641; Humphreys WV, Walker A, Charlesworth D. Altered viscosity and yield stress in patients with abdominal malignancy: relationship to deep vein thrombosis. Br J Surg. 1976;63(7):559–561. PMID: 953452 https://doi.org/10.1002/bjs.1800630715; Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740. PMID: 21403876 https://doi.org/10.4061/2011/394740; Stefan O, Vera N, Otto B, Heinz L, Wolfgang G. Stroke in cancer patients: a risk factor analysis. J Neurooncol. 2009;94(2):221–226. PMID: 19280119 https://doi.org/10.1007/s11060-009-9818-3; Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, et al. Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASISCANCER study. PLoS One. 2016;11:e0159170. PMID: 27427978 https://doi.org/10.1371/journal.pone.0159170; Chung JW, Cho YH, Ahn MJ, Lee MJ, Kim GM, Chung CS, et al. Association of cancer cell type and extracellular vesicles with coagulopathy in patients with lung cancer and stroke. Stroke. 2018;49(5):1282–1285. PMID: 2961026 https://doi.org/10.1161/STROKEAHA.118.020995; Thålin C, Demers M, Blomgren B, Wong SL, von Arbin M, von Heijne A, et al. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res. 2016;139:56–64. PMID: 26916297 https://doi.org/10.1016/j.thromres.2016.01.009; Park H, Kim J, Ha J, Hwang IG, Song TJ, Yoo J, et al. Histological features of intracranial thrombi in stroke patients with cancer. Ann Neurol. 2019;86(1):143–149. PMID: 31025392 https://doi.org/10.1002/ana.25495; Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11(2):223–233. PMID: 23279708 https://doi.org/10.1111/jth.12075; Navi BB, Mathias R, Sherman CP, Wolfe J, Kamel H, Tagawa ST, et al. Cancer-related ischemic stroke has a distinct blood mRNA expression profile. Stroke. 2019;50(11):3259–3264. PMID: 31510897 https://doi.org/10.1161/STROKEAHA.119.026143; Yoo J, Choi JK, Kim YD, Nam HS, Park H, Lee HS, et al. Outcome of Stroke Patients with Cancer and Nonbacterial Thrombotic Endocarditis. Stroke. 2020;22(2):245–253. PMID: 32635688 https://doi.org/10.5853/jos.2020.00619; Seok JM, Kim SG, Kim JW, Chung CS, Kim GM, Lee KH, et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol. 2010;68:213–219. PMID: 32635688 https://doi.org/10.1002/ana.22050; Merkler AE, Navi BB, Singer S, Cheng NT, Stone JB, Kamel H, et al. Diagnostic yield of echocardiography in cancer patients with ischemic stroke. J Neurooncol. 2015;123:115–121. PMID: 25851114 https://doi.org/10.1007/s11060-015-1768-3; Hurrell H, Roberts-Thomson R, Prendergast BD. Non-infective endocarditis. Heart. 2020;106(13):1023–1029. PMID: 32376608 https://doi.org/10.1136/heartjnl-2019-315204; Vinter N, Christesen AMS, Fenger-Grøn M, Tjønneland A, Frost L. Atrial fibrillation and risk of cancer: a Danish population-based cohort study. J Am Heart Assoc. 2018;7(17):e009543. PMID: 30371150 https://doi.org/10.1161/JAHA.118.009543; Mitma AA, Varghese JG, Witt D, Zarich SW. Stroke and a valvular lesion in a patient with stage IV non-small cell lung cancer. BMJ Case Rep. 2016;2016:bcr2016215317. PMID: 27247207 https://doi.org/10.1136/bcr-2016-215317; Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860– 867. PMID: 12490959 https://doi.org/10.1038/nature01322; Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007;65(12 Pt 2):S140–146. PMID: 18240538 https://doi.org/10.1111/j.1753-4887.2007.tb00352.x; Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949. PMID: 15890981 https://doi.org/10.1161/01.RES.0000163635.62927.34; Frayn K, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia. J Am Heart Assoc. 2012;1:e003467. PMID: 23316323 https://doi.org/10.1161/JAHA.112.003467; Rodríguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. Am J Hypertens. 2014;27(11):1327–1337. PMID: 25150828 https://doi.org/10.1093/ajh/hpu142; Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–2072. PMID: 12379575 https://doi.org/10.1161/01.cir.0000034509.14906.ae; Campen CJ, Kranick SM, Kasner SE, Kessler SK, Zimmerman RA, Lustig R, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012;43:3035–3040. PMID: 22968468 https://doi.org/10.1161/STROKEAHA.112.661561; Xu J, Cao Y. Radiation-induced carotid artery stenosis: a comprehensive review of the literature. Interv Neurol. 2014;2(4):183–192. PMID: 25337087 https://doi.org/10.1159/000363068; Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. PMID: 32382051 https://doi.org/10.1038/s41572-020-0160-6; Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J. 2017;377(12):1119–1131. PMID: 28845751 https://doi.org/10.1056/NEJMoa1707914; Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, Jang HM, et al. Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study. J Stroke. 2017;19(1):77–87. PMID: 28030894 https://doi.org/10.5853/jos.2016.00570; Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–624. PMID: 29231094 https://doi.org/10.1056/NEJMoa1711948; Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al.; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. PMID: 32223112 https://doi.org/10.1056/NEJMoa1915103; Edoxaban for the treatment of coagulopathy in patients with active cancer and acute ischemic stroke: a pilot study. (ENCHASE Study) (ENCHASE). 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT03570281 [Accessed Jul 09.2021]; Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015; 373:697–704. PMID: 26095467 https://doi.org/10.1056/NEJMoa1506623; https://www.jnmp.ru/jour/article/view/1283
-
8Academic Journal
Authors: Lisovskaya, T. V., Smirnova, S. S., Gzgyan, A. M., Kireev, D. E., Salimov, D. F., Popov, R. E., Лисовская, Т. В., Смирнова, С. С., Гзгзян, А. М., Киреев, Д. Е., Салимов, Д. Ф., Попов, Р. Э., Буев, Ю. Е.
Subject Terms: IN VITRO FERTILIZATION, SURROGACY, HIV INFECTION, COMORBID CANCER, ЭКСТРАКОРПОРАЛЬНОЕ ОПЛОДОТВОРЕНИЕ, СУРРОГАТНОЕ МАТЕРИНСТВО, ВИЧ, КОМОРБИДНОЕ ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2021. т. 20. №1; http://elib.usma.ru/handle/usma/6248
Availability: http://elib.usma.ru/handle/usma/6248
-
9Academic Journal
Authors: Borisova, A. R., Ustinova, N. A., Борисова, А. Р., Устинова, Н. А.
Source: Сборник статей
Subject Terms: PSYCHOSOCIAL CARE, CANCER, FAMILY EDUCATION, ANXIETY, ПСИХОСОЦИАЛЬНАЯ ПОМОЩЬ, ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, СЕМЕЙНОЕ ВОСПИТАНИЕ, ТРЕВОЖНОСТЬ
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; http://elib.usma.ru/handle/usma/4247
Availability: http://elib.usma.ru/handle/usma/4247
-
10Academic Journal
Authors: Gushchina, M. A., Ivanova, E. S., Kazaeva, A. V., Valieva, T. V., Гущина, М. А., Иванова, Е. С., Казаева, А. В., Валиева, Т. В.
Source: Сборник статей
Subject Terms: PSYCHOLOGICAL DEFENSE, CANCER, REMISSION, PROJECTION, COMPENSATION, ПСИХОЛОГИЧЕСКАЯ ЗАЩИТА, ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, РЕМИССИЯ, ПРОЕКЦИЯ, КОМПЕНСАЦИЯ
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; http://elib.usma.ru/handle/usma/4254
Availability: http://elib.usma.ru/handle/usma/4254
-
11Academic Journal
Authors: S. E. Sedykh, G. A. Nevinsky, С. Е. Седых, Г. А. Невинский
Contributors: Russian Foundation for Basic Research, scientific projects No. 16-34-60 066 мол_а_дк, No. 16-04-00 603 а, grant from the President of Russian Federation in support of young Russian scientists No. МК-410.2017.4, Российский фонд фундаментальных исследований в рамках научных проектов № 16-34-60 066 мол_а_дк, № 16-04-00 603 а, грант Президента РФ по государственной поддержке молодых российских ученых № МК-410.2017.4
Source: Advances in Molecular Oncology; Том 5, № 4 (2018); 30-40 ; Успехи молекулярной онкологии; Том 5, № 4 (2018); 30-40 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2018-5-4
Subject Terms: онкологическое заболевание, immunoglobulin, bispecific immunoglobulin, therapeutic antibodies, monoclonal antibodies, oncology, cancer disease, иммуноглобулин, биспецифичный иммуноглобулин, терапевтические антитела, моноклональные антитела, онкология
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/172/155; Deyev S.M., Lebedenko E.N. Modern technologies for creating synthetic antibodies for clinical application. Acta Naturae 2009;1(1):32—50. PMID: 22649585.; Redman J.M., Hill E.M., AlDeghaither D., Weiner LM. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 2015;67(2):28—45. DOI:10.1016/j.molimm.2015.04.002. PMID: 25911943.; Deyev S.M., Lebedenko E.N., Petrovskaya L.E. et al. Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering. Russian Chemical Reviews 2015;84(1):1—26. DOI:10.1070/RCR4459.; Василенко Е.А., Мохонов В.В., Горшкова Е.Н., Астраханцева И.В. Биспецифические антитела: формы и области применения. Молекулярная биология 2018;52(3):380—93. DOI:10.7868/S0026898418030035.; Zhang X., Yang Y., Fan D., Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol 2017;6(1):12. DOI:10.1186/s40164-017-0072-7. PMID: 28469973.; Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012;4(2):182—97. DOI:10.4161/mabs.4.2.19000. PMID: 22453100.; Sedykh S., Prinz V., Buneva V., Nevinsky G. Bispecific antibodies: design, therapy, perspectives. Drug Design, Development and Therapy 2018;12:195-208. DOI:10.2147/DDDT.S151282.; Spiess C., Zhai Q., Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67(2):95—106. DOI:10.1016/j.molimm.2015.01.003. PMID: 25637431.; Wu C., Ying H., Grinnell C. et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007;25(11):1290—7. DOI:10.1038/nbt1345. PMID: 17934452.; Jakob C.G., Edalji R., Judge R. et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-IgTM) molecule. MAbs 2013;5(3): 358—63. DOI:10.4161/mabs.23977. PMID: 23549062.; Hu S., Fu W., Xu W. et al. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015;75(1):159—70. DOI:10.1158/0008-5472.CAN-14-1670. PMID: 25371409.; Correia I., Sung J., Burton R. et al. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs 2013;5(3):364—72. DOI:10.4161/mabs.24258. PMID: 23572180.; Brennan M., Davison P.F., Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science (New York, NY) 1985;229(4708):81—3.; Doppalapudi V.R,. Tryder N., Li L. et al. Chemically programmed antibodies: En-dothelin receptor targeting CovX-Bodies-TM. Bioorg Med Chem Lett 2007;17(2):501—6. DOI:10.1016/j.bmcl.2006.10.009. PMID: 17055724.; Lum L.G., Thakur A., Liu Q. et al. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2013;19(6):925—33. DOI:10.1016/j.bbmt.2013.03.010. PMID: 23529012.; Chang C.H., Rossi E.A., Goldenberg D.M. The dock-and-lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13(18):5586s—91s. DOI:10.1158/1078-0432.CCR-07-1217.; Rossi E.A., Goldenberg D.M., Cardillo T.M. et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009;113(24):6161—71. DOI:10.1182/blood-2008-10-187138. PMID: 19372261.; Rossi E.A., Rossi D.L., Stein R. et al. A bispecific antibody-ifn 2b immunocyto-kine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010;70(19):7600—9. DOI:10.1158/0008-5472.CAN-10-2126.; Rossi D.L., Rossi E.A., Cardillo T.M. et al. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs 2014;6(2):381 —91. DOI:10.4161/mabs.27385. PMID: 24492297.; Mhller D., Karle A., MeiBburger B. et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007;282(17):12650—60. DOI:10.1074/jbc.M700820200. PMID: 17347147.; Chelius D., Ruf P., Gruber P. et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010;2(3):309—19. DOI:10.4161/mabs.2.3.11791. PMID: 20418662.; Atwell S., Ridgway J.B., Wells JA., Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997;270(1):26—35. DOI:10.1006/jmbi.1997.ni6. PMID: 9231898.; Rispens T., Meesters J., den Bleker T.H. et al. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intrachain hinge isomer. Mol Immunol 2013;53(1—2):35—42. DOI:10.1016/j.mo-limm.2012.06.012. PMID: 22784992.; Bostrom J., Yu S.F., Kan D. et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009;323(5921):1610—4. DOI:10.1126/science.1165480. PMID: 19299620.; Schaefer G., Haber L., Crocker L.M. et al. A Two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20(4):472-86. DOI:10.1016/j.ccr.2011.09.003. PMID: 22014573.; Baeuerle P.A., Kufer P., Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11(1):22—30. PMID: 19169956.; Dreier T., Lorenczewski G., Brandl C. et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100(6):690-7. DOI:10.1002/ijc.10557. PMID: 12209608.; Haas C., Krinner E., Brischwein K. et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214(6):441-53. DOI:10.1016/j.imbio.2008.11.014. PMID: 19157637.; Davies J., Riechmann L. Antibody VH domains as small recognition units. Biotechnology 1995;13(5):475—9. PMID: 9634788.; Els Conrath K., Lauwereys M., Wyns L., Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001;276(10):7346-50. DOI:10.1074/jbc.M007734200. PMID: 11053416.; Kontermann R.E., Brinkmann U. Bispecific antibodies. Drug Discov Today 2015;20(7):838—47. DOI:10.1016/j.drudis.2015.02.008. PMID: 25728220.; Rothe A., Sasse S., Topp M.S. et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;125(26):4024—31. DOI:10.1182/blood-2014-12-614636. PMID: 25887777.; Thakur A., Lum L.G. “NextGen” biologics: bispecific antibodies and emerging clinical results. Expert Opin Biol Ther 2016;16(5):675-88. DOI:10.1517/14712598.2016.1150996. PMID: 26848610.; Bargou R., Leo E., Zugmaier G. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321(5891):974-7. DOI:10.1126/science.1158545. PMID: 18703743.; Nunez-Prado N., Compte M., Harwood S. et al. The coming of age of engineered multivalent antibodies. Drug Discov Today 2015;20(5):588—94. DOI:10.1016/j.drudis.2015.02.013. PMID: 25757598.; Loffler A., Kufer P., LutterbUse R. et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95(6):2098—103. PMID: 10706880.; Wu J., Fu J., Zhang M., Liu D. Blinatu-momab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015;8:104. DOI:10.1186/s13045-015-0195-4. PMID: 26337639.; Goebeler M.E., Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma 2016;57(5):1021—32. DOI:10.3109/10428194.2016.1161185. PMID: 27050240.; Topp M.S., Gokbuget N., Zugmaier G. et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7. DOI:10.1182/blood-2012-07-441030. PMID: 23024237.; Topp M.S., Gokbuget N., Zugmaier G. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32(36):4134—40. DOI:10.1200/JCO.2014.56.3247.; Topp M.S., Kufer P., Gokbuget N. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free Survival. J Clin Oncol 2011;29(18):2493—8. DOI:10.1200/JCO.2010.32.7270. PMID: 21576633.; Aldoss I., Song J., Stiller T. et al. Correlates of resistance and relapse during blina-tumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J He-matol 2017;92(9):858—65. DOI:10.1002/ajh.24783. PMID: 28494518.; Klinger M., Brandl C., Zugmaier G. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119(26):6226—33. DOI:10.1182/blood-2012-01-400515. PMID: 22592608.; Frankel S.R., Baeuerle P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17(3):385—92. DOI:10.1016/j.cbpa.2013.03.029. PMID: 23623807.; Heiss M.M., Murawa P., Koralewski P. et al. The trifunctional antibody catumax-omab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209—21. DOI:10.1002/ijc.25423. PMID: 20473913.; Seimetz D., Lindhofer H., Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36(6):458—67. DOI:10.1016/j.ctrv.2010.03.001.; Linke R., Klein A., Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010;2(2):129—36. DOI:10.4161/mabs.2.2.11221. PMID: 20190561.; Chames P., Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009;1(6):539—47. PMID: 20073127.; Lindhofer H., Mocikat R., Steipe B., Thi-erfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155(1):219—25. PMID: 7602098.; Ruf P. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98(8):2526—34. DOI:10.1182/blood.V98.8.2526. PMID: 11588051.; Ott M.G., Marme F., Moldenhauer G. et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130(9):2195—203. DOI:10.1002/ijc.26258. PMID: 21702044.; van der Neut Kolfschoten M., Schuurman J., Losen M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007;317(5844):1554-7. DOI:10.1126/science.1144603. PMID: 17872445.; Labrijn A.F., Meesters J.I., de Goeij B.E. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013;110(13):5145-50. DOI:10.1073/pnas.1220145110. PMID: 23479652.; Patterson J.T., Gros E., Zhou H. et al. Chemically generated IgG2 bispecific antibodies through disulfide bridging. Bioorg Med Chem Lett 2017;27(16):3647—52. DOI:10.1016/j.bmcl.2017.07.021. PMID: 28720505.; Sedykh S.E., Buneva V.N., Nevinsky G.A. Human milk IgGs contain various combinations of different antigen-binding sites resulting in multiple variants of their bispecificity. PloS One 2012;7(8):e42942. DOI:10.1371/journal.pone.0042942. PMID: 22912765.; Sedykh S.E., Buneva V.N., Nevinsky G.A. Human milk sIgA molecules contain various combinations of different antigenbinding sites resulting in a multiple binding specificity of antibodies and enzymatic activities of abzymes. PloS One 2012;7(11):e48756. DOI:10.1371/journal.pone.0048756. PMID: 23133657.; Sedykh S.E., Lekchnov E.A., Prince V.V. et al. Half molecular exchange of IgGs in the blood of healthy humans: chimeric lambda-kappa-immunoglobulins containing HL fragments of antibodies of different subclasses (IgG1–IgG4). Mol Biosyst 2016;12(10):3186–95. DOI:10.1039/C6MB00479B. PMID: 27506137.; Labrijn A.F., Buijsse A.O., van den Bremer E.T.J. et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009;27(8): 767–71. DOI:10.1038/nbt.1553. PMID: 19620983.; https://umo.abvpress.ru/jour/article/view/172
-
12Academic Journal
Authors: Yatsenko, A.E., Kapustina, T.V., Asriyan, O.B.
Source: Человеческий капитал.
Subject Terms: personality of a cancer patient, ранний детский опыт, детско-родительские отношения, cancer, parent-child relationship, онкологическое заболевание, привязанность, affection, личность онкобольного, early childhood experience, 3. Good health
-
13Academic Journal
Ситуационные и личностные детерминанты совладающего поведения в ситуации онкологического заболевания
Subject Terms: situation of the disease, self, ситуация болезни, интернальность, самоотношение, cancer, internality, совладающее поведение, онкологическое заболевание, assessment of the situation, coulduse behavior, оценка ситуации, 3. Good health
-
14
-
15Dissertation/ Thesis
Authors: Бабина, Е. В.
Contributors: Мельникова, М. Л.
Subject Terms: ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, СМЫСЛОВОЕ БУДУЩЕЕ, ВРЕМЕННАЯ ПЕРСПЕКТИВА, ЖИЗНЕННЫЙ СМЫСЛ, СМЫСЛОЖИЗНЕННЫЕ ОРИЕНТАЦИИ, КОНЦЕПТУАЛЬНАЯ МОДЕЛЬ ФОРМИРОВАНИЯ СМЫСЛОВОГО БУДУЩЕГО
Subject Geographic: USPU
Relation: Кафедра общей психологии и конфликтологии
Availability: https://elar.uspu.ru/handle/ru-uspu/65051
-
16Academic Journal
Authors: Мазурек, Емілія
Source: Visnyk of National Technical University of Ukraine "Kyiv Polytechnic Institute" Philosophy. Psychology. Pedagogics; No. 1 (43) (2015); 105-110 ; Вестник Национального технического университета Украины "КПИ". Философия. Психология. Педагогика; № 1 (43) (2015); 105-110 ; Вісник Національного технічного університету України "КПІ". Філософія. Психологія. Педагогіка; № 1 (43) (2015); 105-110 ; 2308-9393 ; 1683-3309
Subject Terms: education, creativity, activism, patient, cancer, образование, творчество, активность, пациент, онкологическое заболевание, освіта, творчість, активність, пацієнт, онкологічне захворювання
File Description: application/pdf
Availability: http://journal-phipsyped.kpi.ua/article/view/56738
-
17Academic Journal
Authors: Савельева Ольга Николаевна
Subject Terms: психосоматика, онкологическое заболевание, стресс
File Description: text/html
-
18Academic Journal
Authors: Егикян, Манушак
Subject Terms:
ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ,ЛИЧНОСТНАЯ ПОЗИЦИЯ,СТРЕСС,СОЦИАЛЬНАЯ АДАПТАЦИЯ,ДЕПРЕССИЯ,ЛИЧНОСТНАЯ ТРЕВОЖНОСТЬ,СИТУАТИВНАЯ ТРЕВОЖНОСТЬ,ФРУСТРАЦИЯ,"ИНФАНТИЛЬНОСТЬ",КОПИНГ-ПОВЕДЕНИЕ,ШКАЛЫ ИНТЕРНАЛЬНОСТИ,ТОЛЕРАНТНОСТЬ,ЭКСТЕРНАЛИЗАЦИЯ ЛОКУС КОНТРОЛЯ File Description: text/html
-
19Academic Journal
Authors: Ситдикова, И., Вазиев, И., Малеев, М., Алиева, Г., Гайфутдинов, А.
Subject Terms: МАШИНОСТРОИТЕЛЬНОЕ ПРОИЗВОДСТВО, ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, АНКЕТНЫЙ СКРИНИНГ
File Description: text/html
-
20Dissertation/ Thesis
Authors: Проценко, И. А., Protsenko, I. A.
Thesis Advisors: Панкова, С. Н., Pankova, S. N., УрФУ. Уральский гуманитарный институт, Кафедра социальной работы
Subject Terms: МАГИСТЕРСКАЯ ДИССЕРТАЦИЯ, ОНЛАЙН-ВЗАИМОДЕЙСТВИЕ, РЕСУРС, СОЦИАЛЬНАЯ АДАПТАЦИЯ, ОНКОЛОГИЯ, ОНКОЛОГИЧЕСКОЕ ЗАБОЛЕВАНИЕ, СОЦИАЛЬНЫЕ СЕТИ, MASTER'S THESIS, ONLINE INTERACTION, RESOURCE, SOCIAL ADAPTATION, ONCOLOGY, CANCER, SOCIAL NETWORKS
File Description: application/pdf
Availability: http://elar.urfu.ru/handle/10995/106526
